San Diego-based Viking Therapeutics marked itself as a significant competitor inside the weight loss drug marketplace in February just after revealing promising data from the mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in March the compan